Nordea Investment Management AB Acquires 9,196 Shares of Arvinas, Inc. (NASDAQ:ARVN)

Nordea Investment Management AB lifted its holdings in Arvinas, Inc. (NASDAQ:ARVN) by 4.1% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 232,886 shares of the company’s stock after buying an additional 9,196 shares during the quarter. Nordea Investment Management AB’s holdings in Arvinas were worth $4,404,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. nVerses Capital LLC acquired a new stake in Arvinas in the 3rd quarter valued at about $39,000. Quest Partners LLC bought a new stake in shares of Arvinas during the second quarter valued at approximately $42,000. Amalgamated Bank increased its holdings in shares of Arvinas by 29.6% in the second quarter. Amalgamated Bank now owns 2,223 shares of the company’s stock valued at $59,000 after purchasing an additional 508 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in Arvinas by 21.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,483 shares of the company’s stock worth $61,000 after purchasing an additional 440 shares during the last quarter. Finally, Quantbot Technologies LP lifted its holdings in Arvinas by 147.3% during the 3rd quarter. Quantbot Technologies LP now owns 4,367 shares of the company’s stock worth $108,000 after buying an additional 2,601 shares in the last quarter. Institutional investors and hedge funds own 95.19% of the company’s stock.

Arvinas Stock Down 6.1 %

Shares of ARVN stock opened at $18.62 on Friday. The firm has a market cap of $1.28 billion, a PE ratio of -3.99 and a beta of 1.87. Arvinas, Inc. has a 12 month low of $17.37 and a 12 month high of $53.08. The company’s fifty day simple moving average is $22.74 and its 200-day simple moving average is $24.90.

Arvinas (NASDAQ:ARVN) last posted its quarterly earnings data on Wednesday, October 30th. The company reported ($0.68) EPS for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.20. The business had revenue of $102.40 million for the quarter, compared to analyst estimates of $60.56 million. The company’s quarterly revenue was up 196.0% on a year-over-year basis. During the same quarter in the prior year, the company earned ($1.18) earnings per share. On average, equities analysts predict that Arvinas, Inc. will post -3.22 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently commented on ARVN. Stephens initiated coverage on Arvinas in a research note on Monday, November 18th. They issued an “overweight” rating and a $55.00 target price for the company. Oppenheimer dropped their price objective on Arvinas from $50.00 to $40.00 and set an “outperform” rating for the company in a report on Thursday, October 31st. BMO Capital Markets reduced their target price on shares of Arvinas from $90.00 to $88.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 20th. BTIG Research assumed coverage on shares of Arvinas in a research note on Tuesday, December 10th. They set a “buy” rating and a $69.00 price target for the company. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $87.00 price objective on shares of Arvinas in a research note on Wednesday, December 11th. One investment analyst has rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, Arvinas presently has an average rating of “Moderate Buy” and a consensus target price of $63.50.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.